Molecular Weight(MW): 272.38
Estradiol, or more precisely, 17β-estradiol, is a human sex hormone and steroid, and the primary female sex hormone.
Purity & Quality Control
Choose Selective Estrogen/progestogen Receptor Inhibitors
|Description||Estradiol, or more precisely, 17β-estradiol, is a human sex hormone and steroid, and the primary female sex hormone.|
Estradiol induces new dendritic spines and synapses on hippocampal CA1 pyramidal cells. Estradiol treatment resulted in a 46% increase in NMDA receptor binding. Estradiol treatment increases NMDA receptor binding in parallel with dendritic spine and synapse density. Estradiol treatment results in increased sensitivity of CA1 pyramidal cells to NMDA receptor-mediated synaptic input and that this increase is well correlated with the estradiol-induced increase in dendritic spine density in the apical dendritic tree of these cells.  17 beta-estradiol is found to reduce Ba2+ entry reversibly via Ca2+ channels in acutely dissociated and cultured neostriatal neurons. 17 alpha-Estradiol also reduces Ba2+ currents but is significantly less effective than 17 beta-estradiol in rat neostriatal neurons.  17 beta-estradiol exerts a dose-dependent inhibition of IL-1-, TNF-, and IL-1 and TNF-induced production of bioassayable IL-6. Estradiol inhibits both TNF-induced IL-6 production and osteoclast development in primary bone cell cultures derived from neonatal murine calvaria. 
|In vivo||Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat.  Estradiol alone can reverse the ovariectomy-induced decrease in spine density. Estradiol combined with Progesterone initially increases spine density for a period of 2 to 6 hours but then results in a much sharper decrease than is observed following estradiol alone. |
-  Woolley CS, et al. J Neurosci, 1997, 17(5), 1848-1859.
-  Mermelstein PG, et al. J Neurosci, 1996, 16(2), 595-604.
-  Girasole G, et al. J Clin Invest, 1992, 89(3), 883-891.
|In vitro||DMSO||54 mg/mL (198.25 mM)|
|Ethanol||5 mg/mL (18.35 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01923298||Active, not recruiting||Estrogen Levels Among Breast Cancer Patients||University of Arizona||August 9, 2013||Phase 2|
|NCT00370019||Withdrawn||Premature Ovarian Failure||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)||August 25, 2006||Phase 2|
|NCT03043924||Not yet recruiting||Polycystic Ovary Syndrome||University Hospital, Lille|National Research Agency, France||March 2017||--|
|NCT03018366||Recruiting||Estrogen Deficiency|Cardiovascular Disease (CVD)|Hypothalamic Amenorrhea||Cedars-Sinai Medical Center||January 2017||Phase 2|
|NCT03003949||Not yet recruiting||Perimenopausal Disorder|Stress, Emotional||University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)||January 2017||--|
|NCT02792153||Recruiting||Anorexia Nervosa||Johns Hopkins University||December 2016||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.